| Company name (CEO name) | Compensation in U.S. dollars |
|---|---|
| United Therapeutics (Martine Rothblatt) | 45,635,037 |
| UroGen Pharma (Elizabeth Barrett) | 25,900,823 |
| Editas Medicine (Cynthia Collins) | 14,489,736 |
| MeiraGTx (Alexandria Forbes) | 8,480,263 |
| Gossamer Bio (Sheila Gujrathi) | 6,245,606 |
| Halozyme Therapeutics (Helen I. Torley) | 5,857,126 |
| Intra-Cellular Therapies (Sharon Mates) | 4,724,560 |
| Veracyte (Bonnie H. Anderson) | 4,161,963 |
| Iovance Biotherapeutics (Maria Fardis) | 4,107,960 |
| Syros Pharmaceuticals (Nancy A. Simonian) | 3,614,019 |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Source
Release date
September 2020
More information
Region
Worldwide
Survey time period
2019
Supplementary notes
CEO compensation includes base salary, cash bonuses and long-term stock and option awards, as described in annual proxy filings.
Citation formats
